H Lundbeck A/S
CSE:HLUN A

Watchlist Manager
H Lundbeck A/S Logo
H Lundbeck A/S
CSE:HLUN A
Watchlist
Price: 33.65 DKK 2.12%
Market Cap: 33.5B DKK
Have any thoughts about
H Lundbeck A/S?
Write Note

Operating Margin
H Lundbeck A/S

18.3%
Current
18%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
18.3%
=
Operating Profit
3.9B
/
Revenue
21.4B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
DK
H Lundbeck A/S
CSE:HLUN A
33.4B DKK
18%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
729.3B USD
35%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK
44%
US
Johnson & Johnson
NYSE:JNJ
347.8B USD
28%
US
Merck & Co Inc
NYSE:MRK
248.3B USD
34%
CH
Roche Holding AG
SIX:ROG
199.4B CHF
32%
UK
AstraZeneca PLC
LSE:AZN
161.4B GBP
21%
CH
Novartis AG
SIX:NOVN
170.9B CHF
31%
US
Pfizer Inc
NYSE:PFE
149.4B USD
22%
Country DK
Market Cap 33.4B DKK
Operating Margin
18%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 729.3B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.8T DKK
Operating Margin
44%
Country US
Market Cap 347.8B USD
Operating Margin
28%
Country US
Market Cap 248.3B USD
Operating Margin
34%
Country CH
Market Cap 199.4B CHF
Operating Margin
32%
Country UK
Market Cap 161.4B GBP
Operating Margin
21%
Country CH
Market Cap 170.9B CHF
Operating Margin
31%
Country US
Market Cap 149.4B USD
Operating Margin
22%
No Stocks Found

H Lundbeck A/S
Glance View

Market Cap
33.4B DKK
Industry
Pharmaceuticals

Founded in 1915 by Hans Lundbeck, H. Lundbeck A/S has grown from a small trading company into a notable player within the pharmaceutical industry, specializing in the treatment of brain diseases. Over the decades, the company honed its focus on neuroscience, particularly targeting mental health disorders. This specialization has allowed Lundbeck to establish a strong presence in the therapeutic areas of depression, schizophrenia, Alzheimer's, and Parkinson's diseases. The company's operations are grounded in a rigorous commitment to research and development, constantly seeking breakthroughs that can transform mental health treatment. A significant portion of its revenue is channeled back into R&D to maintain its pipeline of innovative pharmaceuticals, ensuring a future driven by new drug discoveries that align with patient needs. Lundbeck’s revenue streams primarily stem from its portfolio of prescription medicines, marketed globally across numerous countries. The company capitalizes particularly on a few blockbuster drugs, forming strategic alliances and partnerships to expand its reach and efficacy. Through a robust distribution network, Lundbeck effectively channels its products from manufacturing through to consumers, including hospitals and pharmacies. Moreover, the company benefits from strategic collaborations with other pharmaceutical giants, enhancing its footprint in competitive markets. By continually investing in cutting-edge research and leveraging strategic partnerships, Lundbeck maintains its mission of delivering effective central nervous system therapies, ensuring a sustainable growth trajectory.

HLUN A Intrinsic Value
65.73 DKK
Undervaluation 49%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
18.3%
=
Operating Profit
3.9B
/
Revenue
21.4B
What is the Operating Margin of H Lundbeck A/S?

Based on H Lundbeck A/S's most recent financial statements, the company has Operating Margin of 18.3%.